StudyFinder
Treatment of Refractory Nausea
Status: Recruiting
We are studying different drugs for the treatment of nausea and vomiting that is caused by chemotherapy treatment of people who have breast cancer.
Sex: Female
Age Group: 18 years and over
Inclusion Criteria:
• diagnosis of breast cancer and not yet started chemotherapy
• scheduled to receive a single-day chemotherapy regimen that contains doxorubicin and/or cyclophosphamide and/or carboplatin
• scheduled to receive an antiemetic regimen that does not contain Akynzeo
Exclusion Criteria:
• clinical evidence of current or impending bowel obstruction
• history of central nervous system disease (e.g., brain metastases or a seizure disorder)
• uncontrolled diabetes mellitus or uncontrolled hyperglycemia
• long term treatment (> 5 days within the past 30 days) with an antipsychotic agent such as risperidone, quetiapine, clozapine, a phenothiazine, or a butyrophenone within 30 days before enrollment or plans for such treatment during the study period
• taking benzodiazepines regularly (> 5 days within the past 30 days); (PRN) use (=< 5 days) for the short-term relief of the symptoms of anxiety, anxiety associated with depressive symptoms
Interventions:
Drug: Dexamethasone, Other: Laboratory Biomarker Analysis, Drug: Netupitant/Palonosetron Hydrochloride, Drug: Olanzapine, Other: Placebo, Drug: Prochlorperazine, Other: Quality-of-Life Assessment
Conditions:
Cancer
Keywords:
Breast Cancer, Breast Cancer, Chemotherapy, Nausea
Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Kiran Lassi
Phase: PHASE3
IRB Number: MMCORC057
See this study on ClinicalTrials.gov